GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Institutional Ownership

Cybin (CYBN) Institutional Ownership : 1.16% (As of Jun. 09, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cybin's institutional ownership is 1.16%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cybin's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cybin's Float Percentage Of Total Shares Outstanding is 0.00%.


Cybin Institutional Ownership Historical Data

The historical data trend for Cybin's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Institutional Ownership Chart

Cybin Historical Data

The historical data trend for Cybin can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 2.25 2.38 2.01 2.35 1.16 1.17 1.04 0.98 1.16 1.16

Cybin Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cybin (CYBN) Business Description

Traded in Other Exchanges
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.